Pomalidomide-d5

Pomalidomide-d5 is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

Product Specifications

CAS Number

[1377838-49-7]

Product Name Alternative

CC-4047-d5

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Apoptosis; Isotope-Labeled Compounds; Ligands for E3 Ligase; Molecular Glues

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Others; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

NC1=C2C(C(N(C2=O)C3(C(NC(C([2H])(C3([2H])[2H])[2H])=O)=O)[2H])=O)=CC=C1

Molecular Formula

C13H6D5N3O4

Molecular Weight

278.27

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11 (16) :5984-92.|[3]Li Z, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8 (8) :e71754.|[4]Liu D, et al. Tumour necrosis factor-α inhibits hepatic lipid deposition through GSK-3β/β-catenin signaling in juvenile turbot (Scophthalmus maximus L.) . Gen Comp Endocrinol. 2016 Mar 1;228:1-8.|[5]Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22 (6) :755-63.|[6]Schafer PH, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 Jun;305 (3) :1222-32.|[7]Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54 (4) :683-7.